<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Latanoprost: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Latanoprost: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Latanoprost: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10791" href="/d/html/10791.html" rel="external">see "Latanoprost: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="117285" href="/d/html/117285.html" rel="external">see "Latanoprost: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F187060"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Iyuzeh;</li>
<li>Xalatan;</li>
<li>Xelpros</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867329"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Latanoprost;</li>
<li>JAMP Latanoprost;</li>
<li>M-Latanoprost;</li>
<li>MED-Latanoprost;</li>
<li>Monoprost;</li>
<li>MYLAN-Latanoprost;</li>
<li>RIVA-Latanoprost;</li>
<li>SANDOZ Latanoprost;</li>
<li>TEVA-Latanoprost;</li>
<li>Xalatan</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F187090"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Ophthalmic Agent, Antiglaucoma;</li>
<li>
                        Prostaglandin, Ophthalmic</li></ul></div>
<div class="block doa drugH1Div" id="F187064"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="60f91e7f-5b7f-4b65-8d79-2634ab361d31">Elevated intraocular pressure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Elevated intraocular pressure:</b> Ophthalmic: One drop in the affected eye(s) once daily in the evening; do not exceed the once daily dosage (may decrease the IOP-lowering effect)</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990698"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There is no dosage adjustment provided in manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doha drugH1Div" id="F50988025"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There is no dosage adjustment provided in manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block doe drugH1Div" id="F187065"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F52812526"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="117285" href="/d/html/117285.html" rel="external">see "Latanoprost: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5332ff24-efe4-4b12-855a-dc42e069756a">Glaucoma, elevated intraocular pressure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Glaucoma</b>
<b>, elevated intraocular pressure:</b> Limited data available: Infants, Children, and Adolescents: Ophthalmic solution (eg, Xalatan): Ophthalmic: 1 drop to affected eye(s) once daily in the evening (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23524858','lexi-content-ref-28957960','lexi-content-ref-30194929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23524858','lexi-content-ref-28957960','lexi-content-ref-30194929'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F52729744"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block dohp drugH1Div" id="F52729745"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.</p></div>
<div class="block adr drugH1Div" id="F187036"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Ophthalmic: Abnormal sensation in eyes (14%), conjunctival hyperemia (8% to 34%), eye discharge (12%), eye irritation (19%), eye pain (≤55%), eye pruritus (5% to 15%), foreign body sensation of eye (2% to 13%), increased eyelash length (11%), ocular hyperemia (41%), stinging of eyes (≤55%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Allergic skin reaction (≤1%, including eyelid), skin rash (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (≤3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≤1%), back pain (≤1%), myalgia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharitis (1%), blurred vision (7% to 8%), burning sensation of eyes (7%), conjunctival edema (1%), crusting of eyelid (3%), decreased visual acuity (4%), dry eye syndrome (3%), erythema of eyelid (3%), eyelid edema (1% to 2%), eyelid pain (4%), hyperpigmentation of eyelashes (1%), increased eyelash thickness (8%), iris hyperpigmentation (7%), lacrimation (4% to 5%), photophobia (2% to 3%), punctate keratitis (1% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (≤3%), upper respiratory tract infection (≤3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris (including unstable angina pectoris), chest pain, palpitations</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness, headache</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (including pseudopemphigoid of the ocular conjunctiva), corneal edema, corneal erosion, deepening of the eyelid sulcus, herpes simplex keratitis, hyperpigmentation of eyelid, hypertrichosis of eyelid, iris cyst, iritis, keratitis, macular edema (including cystoid macular edema), misdirected growth of eyelashes (including trichiasis), uveitis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma (including exacerbation of asthma), dyspnea</p></div>
<div class="block coi drugH1Div" id="F187049"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to latanoprost, benzalkonium chloride, or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F187033"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions, has caused bacterial keratitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular effects: May change/increase brown pigmentation of the iris, the eyelid skin, and eyelashes; length and/or number of eyelashes may also be increased. Pigmentation of the iris is likely to be permanent although iris color change may not be noticeable for months to years; pigmentation of the periorbital tissue and eyelash changes may be reversible following discontinuation of therapy. Long-term consequences and potential injury to eye are not known.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular inflammation: Intraocular inflammation and exacerbation of inflammation may occur; use with caution in patients with a history of intraocular inflammation (eg, iritis/uveitis) and generally avoid use in patients with active intraocular inflammation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Herpetic keratitis: Use with caution in patients with a history of herpes simplex keratitis; reactivation may occur. Avoid use in patients with active herpes simplex keratitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular disease: Use with caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with risk factors for macular edema. Safety and efficacy have not been determined for use in patients with angle-closure, inflammatory, or neovascular glaucoma.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Contact lens wearers: Solution contains benzalkonium chloride which may be absorbed by contact lenses; remove contacts prior to administration and wait 15 minutes before reinserting.</p></div>
<div class="block foc drugH1Div" id="F187043"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Emulsion, Ophthalmic: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xelpros: 0.005% (2.5 mL) [contains edetate (edta) disodium, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Iyuzeh: 0.005% (5 ea) [contains edetate (edta) disodium, peg-40 hydrog castor oil(cremophor rh40)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xalatan: 0.005% (2.5 mL) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.005% (2.5 mL)</p></div>
<div class="block geq drugH1Div" id="F187029"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F187051"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Emulsion</b> (Xelpros Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.005% (per mL): $28.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Iyuzeh Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.005% (per each): $11.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Latanoprost Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.005% (per mL): $3.63 - $38.11</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Xalatan Ophthalmic)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.005% (per mL): $120.82</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867330"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Ophthalmic: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Monoprost: 0.005% (0.2 mL) [contains edetate (edta) disodium]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xalatan: 0.005% (2.5 mL) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.005% (2.5 mL, 5 mL)</p></div>
<div class="block adm drugH1Div" id="F187046"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Ophthalmic:</b> Wash hands prior to use. May be used with other eye drops to lower intraocular pressure. If more than 1 topical ophthalmic drug is being used, administer the drugs at least 5 minutes apart. Remove contact lenses prior to administration and wait 15 minutes before reinserting.</p></div>
<div class="block admp drugH1Div" id="F52613131"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Ophthalmic: Wash hands before use.</p>
<p style="text-indent:-2em;margin-left:4em;">Solution (eg, Xalatan): Unscrew the cap by turning in the direction of the arrows on top of the cap. Pull lower eyelid down slightly to form a pocket for the eye drop and tilt head back; administer 1 drop. Apply gentle pressure to lacrimal sac immediately following instillation (1 minute) or instruct patient to gently close eyelid after administration to decrease systemic absorption of ophthalmic drops (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8100087','lexi-content-ref-6704011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8100087','lexi-content-ref-6704011'])">Ref</a></span>). Avoid contact of bottle tip with skin or eye; remove contact lenses prior to administration and wait at least 15 minutes after instillation before reinserting soft contact lenses. If more than one topical ophthalmic drug is being used, separate administration by at least 5 minutes.</p></div>
<div class="block use drugH1Div" id="F187044"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Elevated intraocular pressure:</b> Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.</p></div>
<div class="block mst drugH1Div" id="F187095"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Latanoprost may be confused with Lantus</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Xalatan may be confused with Lantus, Travatan, Xalacom, Zarontin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299578"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F187038"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents (Ophthalmic) may enhance the therapeutic effect of Prostaglandins (Ophthalmic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostaglandins (Ophthalmic): The concomitant use of Prostaglandins (Ophthalmic) and Latanoprost may result in increased intraocular pressure. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54898479"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Ophthalmic prostaglandins, such as latanoprost, have a theoretical risk of miscarriage. To decrease this risk, agents other than latanoprost may be preferred for the treatment of glaucoma in patients planning to become pregnant (Strelow 2020).</p></div>
<div class="block pri drugH1Div" id="F13376205"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Information related to latanoprost use in pregnancy is limited (DeSantis 2004).</p>
<p style="text-indent:0em;margin-top:2em;">Ophthalmic prostaglandins, such as latanoprost, are generally avoided during pregnancy due to a theoretical risk of miscarriage and premature labor. Agents other than latanoprost may be preferred for the treatment of glaucoma during pregnancy, especially during the first trimester. In general, if ophthalmic agents are needed in pregnancy, the minimum effective dose should be used in combination with punctal occlusion to decrease exposure to the fetus (Belkin 2020; Prum 2016; Strelow 2020).</p></div>
<div class="block brc drugH1Div" id="F20547788"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if latanoprost is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Due to their short half-lives, ophthalmic prostaglandins, such as latanoprost, are considered compatible with breastfeeding; administering after breastfeeding may help decrease potential exposure to the infant via breast milk (Belkin 2020; Prum 2016; Strelow 2020).</p></div>
<div class="block mop drugH1Div" id="F26834799"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor IOP; regularly examine patients who develop increased iris pigmentation.</p></div>
<div class="block pha drugH1Div" id="F187032"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Latanoprost is a prostaglandin F<sub>2</sub>-alpha analog believed to reduce intraocular pressure by increasing the outflow of the aqueous humor</p></div>
<div class="block phk drugH1Div" id="F187048"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 3 to 4 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Maximum: 8 to 12 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Through the cornea where the isopropyl ester prodrug is hydrolyzed by esterases to the biologically active acid. Peak concentration is reached in 2 hours after topical administration in the aqueous humor.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 0.16 ± 0.02 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily hepatic via fatty acid beta-oxidation</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 17 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F187052"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Loprost | Xalatan</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Glaucogesic | Glaucostat | Klonaprost | Latanoflax | Latanoprost dorf | Louten | Ocuprost | Oftal Mix | Oftalpres | Paraiop | Tanamof | Xalatan</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Akistan | Arulatan | Glaukodoc | Latacris | Latano Vision | Latanoprost Agepha | Latanoprost Pfizer | Latanoprost Sandoz | Latanoprost stada | Latanoprost unimed | Latanoratio | Xalatan</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo latanoprost | Chemmart latanoprost | Lanpro | Latanoprost actavis | Latanoprost gh | Latanoprost Pfizer | Latanoprost Sandoz | Terry white chemists latanoprost | Xalaprost | Xalatan</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Iprost | Ocuprost | Xalaprost</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Latanoprost Apotex | Latanoprost EG | Latanoprost mylan | Latanoprost noridem | Latanoprost Pfizer | Latanoprost Sandoz | Latanotears | Monoprost | Vizilatan | Xalatan</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Cexolan | Ioprost | Xalatan</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Akistan | Glautan | Latalux | Latanoprost actavis | Unilat | Xalatan</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Arulatan | Drenatan | Latanoprosta | Xalatan | Xaloftal</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Latano Vision | Latanofta | Latanoprost helvepharm | Latanoprost mepha | Latanoprost Pfizer | Latanoprost spirig hc | Xalatan</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Cexolan | Ioprost | Retilys</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Gaap ofteno pf | Gaax | Latof | Latof sp | Louten | Monoprost | Tomme | Xalatan</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Sheng ao | Te li jie | Xalatan</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Balanprost | Gaap ofteno | Glaucoftal | Kairos pf | Latanox | Latavital | Louten | Oftidon | Xalatan</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Akistan | Arulatan | Glaucotens | Latalux | Latanoprost actavis | Latanoprost Apotex | Latanoprost olikla | Latanoprost Pos | Latanoprost Ratiopharm | Latanoprost stada | Monopost | Solusin | Unilat | Vizilatan | Xalatan | Xaloptic | Zeleza</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Akistan | Arulatan | Emerlatan | Laprost | Latan Ophtal | Latanelb | Latano Q | Latanomed | Latanoprost 1a pharma | Latanoprost abz | Latanoprost actavis | Latanoprost AL | Latanoprost fdc | Latanoprost Hexal | Latanoprost Pfizer | Latanoprost Pos | Latanoprost Ratiopharm | Latanoprost stada | Latanoprost Stulln | Latanoprost Trb | Lifog | Xalatan</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Gaap | Latanox | Latof | Xalatan | Xaloptic</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Exalo | Gaap | Gaap ofteno pf | Larsan | Latof | Latof sp | Louten | Xalatan | Xaloptic</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Latanoprost actavis | Latanoprost ntc | Latanoprost Ratiopharm | Latizolil | Unilat | Xalatan | Xaloptic</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Ioprost | Xalatan | Xalatrex</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Arulatan | Latanest | Latanoprost actavis | Latanoprost Apotex | Latanoprost arrow | Latanoprost cinfa | Latanoprost combix | Latanoprost kern pharma | Latanoprost Medical mix | Latanoprost Mylan pharmaceuticals | Latanoprost Normon | Latanoprost Qualigen | Latanoprost Ratiopharm | Latanoprost Sandoz | Latanoprost stada | Latanoprost Tarbis | Latanoprost teva | Latanoprost vir | Theaprost | Tonlit | Xalatan | Xalavista | Xelor</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Latano | Latanostill | Protan</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Latanoprost actavis | Latanoprost arrow | Latanoprost Pfizer | Latanoprost Ratiopharm | Latanoprost Sandoz | Oftastad | Xalatan</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Latanoprost actavis | Latanoprost arrow | Latanoprost Biogaran | Latanoprost Chauvin | Latanoprost EG | Latanoprost mylan | Latanoprost Pfizer | Latanoprost Ranbaxy | Latanoprost Sandoz | Latanoprost teva | Latanoprost zentiva | Latanoprost Zydus | Latazed | Monoprost | Vizilatan | Xalatan</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Latanoprost arrow | Latanoprost Pfizer | Latanoprost Sandoz | Latanoprost teva | Medizol | Xalatan</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Joxar | Latandrops | Lataneau | Latanogan | Lataz | Pharmaprost | Vlepolin | X iop | Xalaprost | Xalatan</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Ioprost | Latanoprost Sandoz | Latanoprost toa | Xalatan</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Latanox | Xalatan</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Akistan | Lanotan | Laprosep | Latanoprost actavis | Latanoprost Pfizer | Latapres | Unilat | Vizilatan | Xalatan</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Lacoma | Lanotan | Latanoprost fahrenheit | Latipress | Xalatan</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Latop | Xalatan | Zanopro</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Latano avenir | Xalatan</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">9 pm | Ioprost | Ioptame | Lacoma | Laprost | Latochek | Latodrops | Latoprost | Xalatan</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Arulatan | Droplatan | Galaxia | Glak | Iopize | Lastafry | Latacris | Latanoprost actavis | Latanoprost doc generi | Latanoprost EG | Latanoprost mylan | Latanoprost ntc | Latanoprost pensa | Latanoprost rat | Latanoprost Sandoz | Latanoprost sifi | Latanostill | Latay | Macusix | Xalatan | Xalost</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Loprost | Normoprost | Xalatan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Latanoprost Amel | Latanoprost Kissei | Latanoprost Krm | Latanoprost mylan | Latanoprost Nitten | Latanoprost Nitto | Latanoprost NP | Latanoprost ns | Latanoprost Sandoz | Latanoprost Sanwa | Latanoprost Sawai | Latanoprost Senju | Latanoprost Takata | Latanoprost Towa | Latanoprost Wakamoto | Xalatan</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Auroprost rt | Lacoma | Laprost | Latano | Latochek | Latoprost rt | Loprost | Xalatan</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Lamutan | Lanotan | Lantel | Latano | Lataro | Latast | Monoprost | Nomatan | Ocustan | Optilatan | Optiratan | Optis | Optizaltan | Ostan | Protan | Xalatan | Xalost | Xelano</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Latano | Xalatan</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Xalatan</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Latalux | Latanoprost actavis | Latanoprost ingen pharma | Latanoprost ntc | Latanoprost Ratiopharm | Latanoprost Sanoswiss | Latizolil | Unilat | Xalatan | Xaloptic</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Latanoprost EG | Latanoprost rph | Latanotears | Xalatan</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Latalux | Latanoprost actavis | Latanoprost ntc | Latanoprost Ratiopharm | Latizolil | Unilat | Xalatan | Xaloptic | Xalvide</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Arulatan | Latano jp | Xalatan</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Ciscotan | Exalo | Gaap ofteno | Kensolub | Kevixkeni | Latanoprost Exakta | Latsol | Lesspio | Outhyp | Procilio st | Rasguna | Sinprein | Xalatan</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Avetaprost | Ioprost | Latandrops | Latanost | Latanostill | Lataprost | Optaprost | Prosdrop | Xalatan</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Drulatan | Lataneks | Latanoprost sandoz eyedrop | Xalatan | Xales</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Latanoprost actavis | Latanoprost bausch&amp;lomb | Latanoprost cf | Latanoprost mylan | Latanoprost Pfizer | Latanoprost Pos | Latanoprost rp | Latanoprost Sandoz | Latanoprost teva | Vizilatan | Xalatan</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Glauprost | Latanoprost Sandoz | Monoprost | Xalatan</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Hysite | Xalatan</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Gaap ofteno | Hoprix | Latanox | Latof | Latof sp | Latoprost | Louten | Vistavit L | Xalacar | Xalaprost | Xalatan | Xaloptic | Xaloptic sr | Zakol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Astapro | Ioprost | Latadin | Latipress | Xalatan | Xalatrex | Xalavist | Xanoprost</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Hilatan | Latan | Latep | Prostilet | Xalatan</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Akistan | Apo lataprox | Arulatan | Latalux | Latano Pos | Latanoprost arrow | Latanoprost Genoptim | Latanoprost stada | Latanost | Monoprost | Polprost | Rozaprost | Rozaprost mono | Vizilatan | Xalatan | Xaloptic</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Xalatan | Xelpros</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Enicilfree | Latanoprost actavis | Latanoprost Ciclum | Latanoprost edol | Latanoprost farmoz | Latanoprost generis | Latanoprost germed | Latanoprost pentafarma | Latanoprost Sandoz | Latanoprost teva | Xalatan</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Glaucogesic | Lanoprost | Latanoflax | Latof | Louten</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Loprost | Xalatan</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Arulatan | Glautan | Sifitan | Unilat | Xalatan | Xaloptic</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Glaumax | Glauprost | Lanotan | Latanomol | Latanoprost dia | Latanoprost optic | Latanoprost teva | Prolatan | Trilaktan | Xalatamax | Xalatan</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Latano | Lataprost | Xalatan</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Latanoprost actavis | Latanoprost arrow | Latanoprost bijon | Latanoprost orifarm | Latanoprost Sandoz | Latanoprost stada | Latanoprost teva | Xalatan</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Xalatan</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Latanox | Xalatan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Akistan | Arulatan | Latalux | Latanoprost actavis | Latanoprost olikla | Solusin | Tiopromal | Unilat | Xalatan | Xaloptic</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Lanotan | Lumoprost | Xalaprost | Xalatan | Xaprost</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Lata sp | Latanocol | Latapol | Lataz | Xalatan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Glokoprost | Latapol | Latasopt | Latrost | Pegea | Xalatan</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Latan | Unitan | Xalaprost | Xalatan</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Akistan | Glaumax | Lanotan | Lapronext | Latanox | Latasopt | Prolatan | Xalatan</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Auroprost rt | Xalatan</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Gaap ofteno | Latof | Louten | Vistaclof | Xalatan</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Gaap ofteno | Laprost | Latacof | Latanopress | Latanox | Latros | Xalatan | Xaloptic</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Atana | Ioprost | Ocuprost | Spersatan | Xalatan</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Lacoma | Xalatan</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Xalatan</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32672600">
<a name="32672600"></a>Belkin A, Chen T, DeOliveria AR, Johnson SM, Ramulu PY, Buys YM; American Glaucoma Society and the Canadian Glaucoma Society. A practical guide to the pregnant and breastfeeding patient with glaucoma. <i>Ophthalmol Glaucoma.</i> 2020;3(2):79-89. doi:10.1016/j.ogla.2019.12.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/latanoprost-drug-information/abstract-text/32672600/pubmed" id="32672600" target="_blank">32672600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15289149">
<a name="15289149"></a>De Santis M, Lucchese A, Carducci B, et al. Latanoprost exposure in pregnancy. <i>Am J Ophthalmol</i>. 2004;138(2):305-306. doi: 10.1016/j.ajo.2004.03.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/latanoprost-drug-information/abstract-text/15289149/pubmed" id="15289149" target="_blank">15289149</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Iyuzeh (latanoprost) [prescribing information]. Lexington, MA: Thea Pharma Inc; December 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23524858">
<a name="23524858"></a>Maeda-Chubachi T, Chi-Burris K, Simons B, et al. Impact of age, diagnosis, and history of glaucoma surgery on outcomes in pediatric patients treated with latanoprost. <i>J Glaucoma</i>. 2013;22(8):614-619.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/latanoprost-drug-information/abstract-text/23524858/pubmed" id="23524858" target="_blank">23524858</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Monoprost (latanoprost) [prescribing information]. Oakville, Ontario, Canada: Labtician Ophthalmics Inc.; July 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26581556">
<a name="26581556"></a>Prum BE Jr, Rosenberg LF, Gedde SJ, et al. Primary open-angle glaucoma preferred practice pattern(®) guidelines. <i>Ophthalmology</i>. 2016;123(1):P41-P111. doi:10.1016/j.ophtha.2015.10.053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/latanoprost-drug-information/abstract-text/26581556/pubmed" id="26581556" target="_blank">26581556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28957960">
<a name="28957960"></a>Quaranta L, Biagioli E, Riva I, et al. The Glaucoma Italian Pediatric Study (GIPSy): 1-Year Results. <i>J Glaucoma</i>. 2017;26(11):987-994.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/latanoprost-drug-information/abstract-text/28957960/pubmed" id="28957960" target="_blank">28957960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31922978">
<a name="31922978"></a>Strelow B, Fleischman D. Glaucoma in pregnancy: an update. <i>Curr Opin Ophthalmol.</i> 2020;31(2):114-122. doi:10.1097/ICU.0000000000000641<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/latanoprost-drug-information/abstract-text/31922978/pubmed" id="31922978" target="_blank">31922978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8100087">
<a name="8100087"></a>Urtti A, Salminen L. Minimizing systemic absorption of topically administered ophthalmic drugs. <i>Surv Ophthalmol</i>. 1993;37(6):435-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/latanoprost-drug-information/abstract-text/8100087/pubmed" id="8100087" target="_blank">8100087</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Xalatan (latanoprost) [prescribing information]. New York, NY: Pfizer; September 2020.</div>
</li>
<li>
<div class="reference">
                  Xalatan (latanoprost) [prescribing information]. New York, NY: Pfizer; December 2022.</div>
</li>
<li>
<div class="reference">
                  Xalatan (latanoprost) [product monograph]. Etobicoke, Ontario, Canada: BGP Pharma ULC; July 2023.</div>
</li>
<li>
<div class="reference">
                  Xelpros (latanoprost) [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries Inc; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30194929">
<a name="30194929"></a>Younus M, Schachar RA, Zhang M, et al. A long-term safety study of latanoprost in pediatric patients with glaucoma and ocular hypertension: a prospective cohort study. <i>Am J Ophthalmol</i>. 2018;196:101-111. doi:10.1016/j.ajo.2018.08.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/latanoprost-drug-information/abstract-text/30194929/pubmed" id="30194929" target="_blank">30194929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6704011">
<a name="6704011"></a>Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. <i>Arch Ophthalmol</i>. 1984;102(4):551-553.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/latanoprost-drug-information/abstract-text/6704011/pubmed" id="6704011" target="_blank">6704011</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9547 Version 257.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
